VERU News and Press, Veru Inc. From 08/11/22

Shares of Veru (NASDAQ: VERU) were flying 31.6% higher at 12:14 p.m. ET on Thursday. The big gain came after the drugmaker provided its fiscal 2022 third-quarter update before the market opened. Veru's Q3 results didn't appear to justify the sizable jump for the stock. The compa...

While earnings season is winding down, the release of quarterly results still provided one of the critical catalysts in Thursday's midday action. This included Warby Parker ( WRBY ), which rallied despite a weak forecast, as investors focused on the firm's cost-cutting commitment. E...

Veru Inc. (VERU) Q3 2022 Earnings Conference Call August 11, 2022 08:00 AM ET Company Participants Samuel Fisch - Executive Director, IR & Corporate Communications Mitchell Steiner - Chairman, President & CEO Michele Greco - CFO & Chief Administrative...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock AcelRx Pharmaceuticals (NASDAQ: ACRX ) stock is seeing major gains on Thursday after announcing a presentation for the upcoming Plastic Surgery: The Meeting 2022 . That meeting is set t...

Veru Inc. (NASDAQ: VERU) shares spiked more than 30% on Thursday after the biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and Acute Respiratory Distress Syndrome (ARDS)-related diseases and for the management of breast and prosta...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Veru (NASDAQ: VERU ) stock is heading higher on Thursday as investors celebrate positive news in its earnings report for the fiscal third quarter of 2022. However, it’s not the earn...

Gainers: T2 Biosystems ( TTOO ) +73% . Veru ( VERU ) +38% . Ginkgo Bioworks ( DNA ) +21% . Inotiv ( NOTV ) +20% . Accuray ( ARAY ) +17% . Losers: Athenex ( ATNX ) -46% . Invitae ( NVTA ) -43% . Cer...

Shares of Veru ( NASDAQ: VERU ) gained 20.4% to $14.17 in Thursday premarket trading, as investors looked past the company's Q3 results miss and focused on the potential upside from prospective emergency use approvals for its COVID-19 treatment sabizabulin. Miami, Fla.-b...

Veru press release ( NASDAQ: VERU ): Q2 GAAP EPS of -$0.28 misses by $0.12 . Revenue of $9.6M (-45.6% Y/Y) misses by $7.48M . US FC2 prescription net revenues decreased 50% to $6.7 million from $13.5 million Gross margin decreased to 74% of net revenues fro...

-- Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022-- --The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will Receive Exp...